The Company has already secured orphan drug status for the ovarian indication in the U.S. and is planning additional studies in other indications such as head & neck cancers and Acute Myelogenous Leukemia in addition to Li‐Fraumeni Syndrome, and combination therapies with other leading cancer drugs.
“We are pursuing multiple cancer indications with our lead asset, COTI‐2. The prevalence of p53 gene mutations among people with LFS makes this a highly relevant target for COTI‐2 and its unique mechanism of action. Obtaining an Orphan Drug Designation for COTI‐2 in the treatment of LFS is therefore very attractive to us as the strong scientific rationale, limited competition in a niche market, and significant unmet medical need offers substantial motivation and incentive.” - Dr. Wayne Danter
For more information on Li-Fraumeni Syndrome, readers may wish to view yesterday's article in the Globe and Mail titled: Why does cancer stalk this family?